Ironwood Pharmaceuticals Total Long Term Liabilities 2010-2025 | IRWD

Ironwood Pharmaceuticals total long term liabilities from 2010 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
Ironwood Pharmaceuticals Annual Total Long Term Liabilities
(Millions of US $)
2024 $613
2023 $541
2022 $423
2021 $359
2020 $464
2019 $455
2018 $409
2017 $530
2016 $552
2015 $448
2014 $180
2013 $200
2012 $31
2011 $34
2010 $77
2009 $404
Ironwood Pharmaceuticals Quarterly Total Long Term Liabilities
(Millions of US $)
2025-03-31 $613
2024-12-31 $613
2024-09-30 $651
2024-06-30 $672
2024-03-31 $517
2023-12-31 $541
2023-09-30 $569
2023-06-30 $645
2023-03-31 $425
2022-12-31 $423
2022-09-30 $422
2022-06-30 $420
2022-03-31 $418
2021-12-31 $359
2021-09-30 $354
2021-06-30 $361
2021-03-31 $466
2020-12-31 $464
2020-09-30 $454
2020-06-30 $454
2020-03-31 $448
2019-12-31 $455
2019-09-30 $435
2019-06-30 $424
2019-03-31 $482
2018-12-31 $409
2018-09-30 $501
2018-06-30 $567
2018-03-31 $527
2017-12-31 $530
2017-09-30 $578
2017-06-30 $620
2017-03-31 $593
2016-12-31 $552
2016-09-30 $577
2016-06-30 $528
2016-03-31 $434
2015-12-31 $448
2015-09-30 $445
2015-06-30 $452
2015-03-31 $178
2014-12-31 $180
2014-09-30 $184
2014-06-30 $188
2014-03-31 $191
2013-12-31 $200
2013-09-30 $202
2013-06-30 $201
2013-03-31 $204
2012-12-31 $31
2012-09-30 $29
2012-06-30 $31
2012-03-31 $33
2011-12-31 $34
2011-09-30 $36
2011-06-30 $49
2011-03-31 $67
2010-12-31 $77
2010-09-30 $81
2010-06-30 $91
2010-03-31 $94
2009-12-31 $404
2009-09-30 $374
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.092B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $86.587B 32.48
Zoetis (ZTS) United States $72.382B 27.01
Daiichi Sankyo, - (DSNKY) Japan $50.265B 25.57
Takeda Pharmaceutical (TAK) Japan $46.360B 9.22
Sandoz Group AG (SDZNY) Switzerland $21.683B 0.00
Summit Therapeutics (SMMT) United States $19.198B 0.00
Merck (MKKGY) Germany $16.795B 12.31
United Therapeutics (UTHR) United States $13.877B 12.28
Shionogi (SGIOY) Japan $13.799B 13.82
Neurocrine Biosciences (NBIX) United States $11.894B 40.74
IPSEN (IPSEY) France $9.790B 0.00
Orion OYJ (ORINY) Finland $9.323B 25.21
Corcept Therapeutics (CORT) United States $8.345B 67.84
Stevanato Group S.p.A (STVN) Italy $6.756B 41.31
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $5.941B 0.00
Grifols, S.A (GRFS) Spain $5.576B 0.00
Ionis Pharmaceuticals (IONS) United States $5.249B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.875B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.987B 10.47
Crinetics Pharmaceuticals (CRNX) United States $2.786B 0.00
Hypermarcas (HYPMY) Brazil $2.616B 17.21
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.244B 12.14
BioCryst Pharmaceuticals (BCRX) United States $2.216B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.977B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.719B 0.00
Evotec AG (EVO) Germany $1.680B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.659B 0.00
Indivior (INDV) United States $1.553B 6.58
ARS Pharmaceuticals (SPRY) United States $1.471B 0.00
Guardian Pharmacy Services (GRDN) United States $1.389B 0.00
Dyne Therapeutics (DYN) United States $1.329B 0.00
Ocular Therapeutix (OCUL) United States $1.163B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.092B 21.84
Harrow (HROW) United States $0.950B 0.00
Ardelyx (ARDX) United States $0.950B 0.00
Collegium Pharmaceutical (COLL) United States $0.927B 5.00
Avadel Pharmaceuticals (AVDL) Ireland $0.883B 0.00
Enliven Therapeutics (ELVN) United States $0.805B 0.00
Cronos Group (CRON) Canada $0.782B 0.00
Xeris Biopharma Holdings (XERS) United States $0.755B 0.00
Akebia Therapeutics (AKBA) United States $0.751B 0.00
AleAnna (ANNA) United States $0.675B 0.00
KalVista Pharmaceuticals (KALV) United States $0.570B 0.00
Elite Pharmaceuticals (ELTP) United States $0.566B 0.00
USANA Health Sciences (USNA) United States $0.548B 11.91
Regulus Therapeutics (RGLS) United States $0.546B 0.00
Xencor (XNCR) United States $0.539B 0.00
Bioventus (BVS) United States $0.536B 13.60
Relay Therapeutics (RLAY) United States $0.499B 0.00
Savara (SVRA) United States $0.491B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.473B 0.00
Zevra Therapeutics (ZVRA) United States $0.473B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.465B 0.00
Altimmune (ALT) United States $0.463B 0.00
CytoDyn (CYDY) United States $0.424B 0.00
Siga Technologies (SIGA) United States $0.422B 8.82
Oruka Therapeutics (ORKA) United States $0.410B 0.00
Tourmaline Bio (TRML) United States $0.394B 0.00
Verve Therapeutics (VERV) United States $0.389B 0.00
Organogenesis (ORGO) United States $0.368B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.339B 9.15
Heron Therapeutics (HRTX) United States $0.282B 0.00
Nature's Sunshine Products (NATR) United States $0.262B 24.19
Aquestive Therapeutics (AQST) United States $0.233B 0.00
MediWound (MDWD) Israel $0.220B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.212B 0.00
ProKidney (PROK) United States $0.208B 0.00
Nanobiotix S.A (NBTX) France $0.172B 0.00
Wellgistics Health (WGRX) United States $0.170B 0.00
OmniAb (OABI) United States $0.169B 0.00
Avita Medical (RCEL) United States $0.166B 0.00
Journey Medical (DERM) United States $0.163B 0.00
4D Molecular Therapeutics (FDMT) United States $0.162B 0.00
Esperion Therapeutics (ESPR) United States $0.157B 0.00
Profound Medical (PROF) Canada $0.154B 0.00
Liminatus Pharma (LIMN) $0.145B 0.00
Aclaris Therapeutics (ACRS) United States $0.136B 0.00
Aldeyra Therapeutics (ALDX) United States $0.133B 0.00
Inhibikase Therapeutics (IKT) United States $0.132B 0.00
Korro Bio (KRRO) United States $0.130B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.124B 0.00
Lyell Immunopharma (LYEL) United States $0.123B 0.00
Nektar Therapeutics (NKTR) United States $0.122B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Protara Therapeutics (TARA) United States $0.121B 0.00
Larimar Therapeutics (LRMR) United States $0.120B 0.00
VAXART, INC (VXRT) United States $0.106B 0.00
Achieve Life Sciences (ACHV) Canada $0.105B 0.00
Cassava Sciences (SAVA) United States $0.102B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Lexeo Therapeutics (LXEO) United States $0.094B 0.00
Cardiol Therapeutics (CRDL) Canada $0.091B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.091B 0.00
Fractyl Health (GUTS) United States $0.088B 0.00
Arch Biopartners (ACHFF) Canada $0.084B 0.00
Galectin Therapeutics (GALT) United States $0.081B 0.00
Champions Oncology (CSBR) United States $0.080B 13.18
Pyxis Oncology (PYXS) United States $0.076B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.076B 56.44
ESSA Pharma (EPIX) Canada $0.075B 0.00
Inotiv (NOTV) United States $0.073B 0.00
Surrozen (SRZN) United States $0.068B 0.00
Dominari Holdings (DOMH) United States $0.067B 0.00
Assertio Holdings (ASRT) United States $0.067B 0.00
Vivani Medical (VANI) United States $0.067B 0.00
Unicycive Therapeutics (UNCY) United States $0.067B 0.00
Telomir Pharmaceuticals (TELO) United States $0.063B 0.00
Context Therapeutics (CNTX) United States $0.062B 0.00
Nutriband (NTRB) United States $0.061B 0.00
Metagenomi (MGX) United States $0.061B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.057B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Prelude Therapeutics (PRLD) United States $0.050B 0.00
Century Therapeutics (IPSC) United States $0.048B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.048B 0.00
Mural Oncology (MURA) Ireland $0.047B 0.00
PMV Pharmaceuticals (PMVP) United States $0.047B 0.00
NRx Pharmaceuticals (NRXP) United States $0.045B 0.00
Avalo Therapeutics (AVTX) United States $0.041B 0.00
Karyopharm Therapeutics (KPTI) United States $0.040B 0.00
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
ElectroCore (ECOR) United States $0.037B 0.00
Acrivon Therapeutics (ACRV) United States $0.037B 0.00
Rafael Holdings (RFL) United States $0.035B 0.00
FibroGen (FGEN) United States $0.033B 0.00
SCYNEXIS (SCYX) United States $0.030B 0.00
PolyPid (PYPD) Israel $0.028B 0.00
China SXT Pharmaceuticals (SXTC) China $0.025B 0.00
Enlivex Therapeutics (ENLV) Israel $0.023B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Tempest Therapeutics (TPST) United States $0.023B 0.00
Relmada Therapeutics (RLMD) United States $0.021B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
Jupiter Neurosciences (JUNS) United States $0.021B 0.00
Lipocine (LPCN) United States $0.019B 0.00
BioVie (BIVI) United States $0.019B 0.00
Mannatech (MTEX) United States $0.018B 0.00
DURECT (DRRX) United States $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
VYNE Therapeutics (VYNE) United States $0.016B 0.00
GlycoMimetics (GLYC) United States $0.016B 0.00
SHINECO (SISI) China $0.015B 0.00
MEI Pharma (MEIP) United States $0.014B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.013B 0.00
ProPhase Labs (PRPH) United States $0.013B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.013B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
Scienture Holdings (SCNX) United States $0.011B 0.00
Talphera (TLPH) United States $0.010B 0.00
Minerva Neurosciences (NERV) United States $0.010B 1.78
Ainos (AIMD) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Traws Pharma (TRAW) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Lyra Therapeutics (LYRA) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
Aditxt (ADTX) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00